학술논문
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
Document Type
Article
Author
Balar, Arjun V ; Kamat, Ashish M; Kulkarni, Girish S; Uchio, Edward M; Boormans, Joost L; Roumiguié, Mathieu; Krieger, Laurence E M; Singer, Eric A; Bajorin, Dean F; Grivas, Petros; Seo, Ho Kyung; Nishiyama, Hiroyuki; Konety, Badrinath R; Li, Haojie; Nam, Kijoeng; Kapadia, Ekta; Frenkl, Tara; de Wit, Ronald
Source
In The Lancet Oncology July 2021 22(7):919-930
Subject
Language
ISSN
1470-2045